Scotiabank analyst George Farmer downgraded Sage Therapeutics (SAGE) to Sector Perform from Outperform with a $9.20 price target Supernus Pharmaceuticals (SUPN) has announced an agreement to acquire Sage through a tender offer for $8.50 per share in cash, payable at closing, plus one non-tradable contingent value right collectively worth up to $3.50 per share in cash, for total consideration of $12.00 per share in cash.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- Sage Therapeutics cutting over 330 jobs, Boston Globe reports
- Sage Therapeutics price target lowered to $8.50 from $11 at JPMorgan
- Avidity, BridgeBio, Coty, SAGE, Alkermes: Trending by Analysts
- Sage Therapeutics price target raised to $9 from $7 at Baird
- H.C. Wainwright sees potential competition for Sage from Biogen